Tag: clinical trials
-
Patient Registry Started for Rare Genetic Disorder
29 June 2015. A registry of families with individuals having Sjögren-Larsson syndrome aims to systematically collect data about families’ experiences with the disease and provide a source of participants for clinical trials of therapies. The registry is being formed by the National Organization for Rare Disorders and Sjögren-Larsson Syndrome Network Community. Sjögren-Larsson Syndrome, or SLS,…
-
Novartis Acquires Pain Medication Developer in $200M Deal
29 June 2015. Global pharmaceutical company Novartis is acquiring Spinifex Pharmaceuticals Inc., a developer of new types of therapies for neuropathic pain. Spinifex reports Novartis is paying $200 million in cash for the company — based in Stamford, Connecticut and Melbourne, Australia — as well as undisclosed future milestone payments. Spinifex Pharmaceuticals develops therapies for…
-
Rare Disease Therapy Company Raises $60 Million in IPO
26 June 2015. Catabasis Pharmaceuticals Inc., a biotechnology company creating treatments for rare diseases and cholesterol-related disorders, is raising $60 million in its initial public stock offering, trading on the Nasdaq exchange under the symbol CATB. The Cambridge, Massachusetts enterprise yesterday priced its 5 million shares at $12.00, and as of 4:00 pm today is…
-
Point-of-Care Ebola Test Found Accurate in Field Test
26 June 2015. A commercial point-of-care test detecting Ebola virus in the blood of a patient was shown in a field test in Sierra Leone to be as accurate as tests sent to remote labs for analysis. Results of the study led by Nira Pollock of Harvard Medical School and Boston Children’s Hospital were published…
-
Trial Shows Safety, Benefits of Diabetic Eye Disease Drug
25 June 2015. An early-stage clinical trial of a drug to treat eye disorders caused by diabetes shows the drug is well-tolerated and reduces swelling in the eye associated with the disease. Stealth BioTherapeutics, developer of the drug brand-named Ocuvia, reported the results today at a company symposium in New York City. The study is…
-
Trial Begins Testing Sickle Cell Blood Therapy
23 June 2015. A clinical trial began enrolling participants testing a synthesized therapy for sickle cell disease to improve the flow of blood cells blocked by the condition and relieve the intense pain that results. The late-stage trial is being conducted by drug maker Pfizer Inc., with biotechnology company GlycoMimetics Inc. in Gaithersburg, Maryland. Sickle…
-
Trial Testing Precision Medicine as Skin Cancer Therapy
18 June 2015. A clinical trial is recruiting participants to test targeted molecular therapies as treatments for advanced cases of skin cancer. The study plans to enroll 96 individuals with melanoma, an advanced and dangerous form of skin cancer, found spreading to other organs in the body and cannot be treated with surgery. Melanoma results…
-
Drug Makers Start Prostate Cancer Patient Registry
17 June 2015. Two companies that developed a drug to treat prostate cancer, began enrolling individuals into a registry of people with prostate cancer to track their quality of care. Astellas U.S., a division of Astellas Pharma in Tokyo, and Medivation Inc., a biotechnology company in San Francisco, created the registry to better understand treatment…
-
Report Evaluates Industry-Academic Biotech Partner Roles
16 June 2015. A report released today by Biotechnology Industry Organization, or Bio, indicates academic research labs are playing an increasingly key role in research and development of new therapies, but it also highlights areas where partnerships between academia and industry are still evolving. Bio released the report, Advancing Translational Research for Biomedical Innovation: Measuring…
-
Patent Awarded for Early, Pre-Symptom Cancer Tests
16 June 2015. Three researchers at Kansas State University in Manhattan received a patent for an early-stage test that the inventors say can diagnose some solid tumor cancers well before symptoms develop. Kansas State chemistry professor Stefan Bossmann and anatomy-physiology professor Deryl Troyer, with postdoctoral fellow Matthew Basel, received U.S. patent number 8,969,027 in March…